undamentalytics Newsletter
Sign in

Endovia Health Sciences, Inc. revenue

Endovia Health Sciences, Inc.'s revenue was $73,066 in fiscal 2025, down 90.9% on the year before. Since fiscal 2011 ($283,828) it has grown at a compound -9.2% a year. Over the last twelve months it was $32,090.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0001111102111819100
Growth on the year before—+8.8%+53.9%+27.5%+48.1%+12.8%−11.6%+46.2%−98.4%+>999%+392.0%+59.8%+4.2%−95.7%−90.9%—
Gross profit00000101−00466−000

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
E Commerce $59,012 80.8% ▼ 90.9%
Splash Beverage Group $14,054 19.2% ▼ 90.9%

From Endovia Health Sciences, Inc.'s 10-K filed April 15, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Beverages: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Endovia Health Sciences, Inc. $32,090 -90.9% -88.4%
LQR House Inc. $1.2m -49.6% 12.8%
Innovation Beverage Group Ltd $2.8m -5.1% —
Epsium Enterprise Ltd $5.1m -59.1% —
Agencia Comercial Spirits Ltd. $6.2m 144.6% —
Meiwu Technology Co Ltd $7.1m 4368.0% —

Compare with peers

Head to head: EDVA vs YHCEDVA vs IBGEDVA vs EPSM

More: Beverages stocks compared, Consumer Staples sector, rankings of US companies

Figures from Endovia Health Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Endovia Health Sciences, Inc.